{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T05:38:05Z","timestamp":1791610685399,"version":"4.3.4"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Parkinsons Dis."],"DOI":"10.1038\/s41531-025-01192-9","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T13:54:54Z","timestamp":1766066094000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The genetic architecture of Parkinson\u2019s disease on the Island of Crete"],"prefix":"10.1038","volume":"11","author":[{"given":"Iro","family":"Boura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaimaa","family":"Sait","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos M.","family":"Marinakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumar","family":"Arvind","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Chia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anindita","family":"Ray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giannis","family":"Vatsellas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodoros","family":"Loupis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasiliki","family":"Pavlaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Periklis","family":"Makrythanasis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panayiotis","family":"Mitsias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia","family":"Xiromerisiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja W.","family":"Scholz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cleanthe","family":"Spanaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,18]]},"reference":[{"key":"1192_CR1","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/S1474-4422(19)30287-X","volume":"19","author":"C Blauwendraat","year":"2020","unstructured":"Blauwendraat, C., Nalls, M. A. & Singleton, A. B. The genetic architecture of Parkinson\u2019s disease. Lancet Neurol. 19, 170\u2013178 (2020).","journal-title":"Lancet Neurol."},{"key":"1192_CR2","doi-asserted-by":"publisher","unstructured":"Jia, F., Fellner, A. & Kumar, K. R. Monogenic Parkinson\u2019s disease: genotype, phenotype, pathophysiology, and genetic testing. Genes 13, https:\/\/doi.org\/10.3390\/genes13030471 (2022).","DOI":"10.3390\/genes13030471"},{"key":"1192_CR3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41531-023-00608-8","volume":"10","author":"V Pitz","year":"2024","unstructured":"Pitz, V. et al. Analysis of rare Parkinson\u2019s disease variants in millions of people. NPJ Park. Dis. 10, 11 (2024).","journal-title":"NPJ Park. Dis."},{"key":"1192_CR4","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1002\/ana.24335","volume":"77","author":"V Escott-Price","year":"2015","unstructured":"Escott-Price, V. et al. Polygenic risk of Parkinson disease is correlated with disease age at onset. Ann. Neurol. 77, 582\u2013591 (2015).","journal-title":"Ann. Neurol."},{"key":"1192_CR5","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1038\/s41593-018-0236-8","volume":"21","author":"TM Dawson","year":"2018","unstructured":"Dawson, T. M., Golde, T. E. & Lagier-Tourenne, C. Animal models of neurodegenerative diseases. Nat. Neurosci. 21, 1370\u20131379 (2018).","journal-title":"Nat. Neurosci."},{"key":"1192_CR6","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1007\/s13311-020-00920-8","volume":"17","author":"SA Schneider","year":"2020","unstructured":"Schneider, S. A., Hizli, B. & Alcalay, R. N. Emerging targeted therapeutics for genetic subtypes of Parkinsonism. Neurotherapeutics 17, 1378\u20131392 (2020).","journal-title":"Neurotherapeutics"},{"key":"1192_CR7","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41421-023-00639-8","volume":"10","author":"H Zhu","year":"2024","unstructured":"Zhu, H., Hixson, P., Ma, W. & Sun, J. Pharmacology of LRRK2 with type I and II kinase inhibitors revealed by cryo-EM. Cell Discov. 10, 10 (2024).","journal-title":"Cell Discov."},{"key":"1192_CR8","doi-asserted-by":"publisher","first-page":"2668","DOI":"10.1093\/brain\/awae142","volume":"147","author":"L Cook","year":"2024","unstructured":"Cook, L. et al. Parkinson\u2019s disease variant detection and disclosure: PD GENEration, a North American study. Brain 147, 2668\u20132679 (2024).","journal-title":"Brain"},{"key":"1192_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.971252","volume":"13","author":"LJ Smith","year":"2022","unstructured":"Smith, L. J., Lee, C. Y., Menozzi, E. & Schapira, A. H. V. Genetic variations in GBA1 and LRRK2 genes: biochemical and clinical consequences in Parkinson\u2019s disease. Front Neurol. 13, 971252 (2022).","journal-title":"Front Neurol."},{"key":"1192_CR10","doi-asserted-by":"publisher","unstructured":"Junker, J. et al. Understanding monogenic Parkinson\u2019s disease at a global scale. medRxiv https:\/\/doi.org\/10.1101\/2024.03.12.24304154 (2024).","DOI":"10.1101\/2024.03.12.24304154"},{"key":"1192_CR11","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1093\/hmg\/11.20.2507","volume":"11","author":"P Heutink","year":"2002","unstructured":"Heutink, P. & Oostra, B. A. Gene finding in genetically isolated populations. Hum. Mol. Genet. 11, 2507\u20132515 (2002).","journal-title":"Hum. Mol. Genet."},{"key":"1192_CR12","unstructured":"Hellenic Statistical Authority. Census Results of Population and Housing, https:\/\/www.statistics.gr\/el\/2021-census-res-pop-results?inheritRedirect=true (2021)."},{"key":"1192_CR13","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1212\/01.WNL.0000113720.71387.88","volume":"62","author":"C Spanaki","year":"2004","unstructured":"Spanaki, C. & Plaitakis, A. Bilineal transmission of Parkinson\u2019s disease on Crete suggests a complex inheritance. Neurology 62, 815\u2013817 (2004).","journal-title":"Neurology"},{"key":"1192_CR14","doi-asserted-by":"publisher","unstructured":"Dhar, D. et al. Islands and neurology: an exploration into a unique association. Neuroscientist, 10738584241257927 https:\/\/doi.org\/10.1177\/10738584241257927 (2024).","DOI":"10.1177\/10738584241257927"},{"key":"1192_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms2871","volume":"4","author":"JR Hughey","year":"2013","unstructured":"Hughey, J. R. et al. A European population in Minoan Bronze Age Crete. Nat. Commun. 4, 1861 (2013).","journal-title":"Nat. Commun."},{"key":"1192_CR16","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/s41559-022-01952-3","volume":"7","author":"E Skourtanioti","year":"2023","unstructured":"Skourtanioti, E. et al. Ancient DNA reveals admixture history and endogamy in the prehistoric Aegean. Nat. Ecol. Evol. 7, 290\u2013303 (2023).","journal-title":"Nat. Ecol. Evol."},{"key":"1192_CR17","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1111\/ahg.12328","volume":"83","author":"P Drineas","year":"2019","unstructured":"Drineas, P. et al. Genetic history of the population of Crete. Ann. Hum. Genet. 83, 373\u2013388 (2019).","journal-title":"Ann. Hum. Genet."},{"key":"1192_CR18","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1111\/j.1469-1809.2007.00414.x","volume":"72","author":"RJ King","year":"2008","unstructured":"King, R. J. et al. Differential Y-chromosome Anatolian influences on the Greek and Cretan Neolithic. Ann. Hum. Genet. 72, 205\u2013214 (2008).","journal-title":"Ann. Hum. Genet."},{"key":"1192_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2024.110799","volume":"85","author":"A Arnaiz-Villena","year":"2024","unstructured":"Arnaiz-Villena, A. et al. Cretan HLA genetics supports its early Minoan culture as a link between North Africa and Europe. Hum. Immunol. 85, 110799 (2024).","journal-title":"Hum. Immunol."},{"key":"1192_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms6345","volume":"5","author":"K Panoutsopoulou","year":"2014","unstructured":"Panoutsopoulou, K. et al. Genetic characterization of Greek population isolates reveals strong genetic drift at missense and trait-associated variants. Nat. Commun. 5, 5345 (2014).","journal-title":"Nat. Commun."},{"key":"1192_CR21","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1212\/01.wnl.0000239829.33936.73","volume":"67","author":"C Spanaki","year":"2006","unstructured":"Spanaki, C., Latsoudis, H. & Plaitakis, A. LRRK2 mutations on Crete: R1441H associated with PD evolving to PSP. Neurology. 67, 1518\u20131519 (2006).","journal-title":"Neurology."},{"key":"1192_CR22","doi-asserted-by":"publisher","first-page":"442.e449","DOI":"10.1016\/j.neurobiolaging.2013.07.011","volume":"35","author":"E Kara","year":"2014","unstructured":"Kara, E. et al. Assessment of Parkinson\u2019s disease risk loci in Greece. Neurobiol. Aging. 35, 442.e449\u2013442.e416 (2014).","journal-title":"Neurobiol. Aging."},{"key":"1192_CR23","doi-asserted-by":"publisher","unstructured":"Boura, I. Mitsias, P., Erimaki, S., Papadaki, E., Spanaki, C. A new phenotype-genotype correlation for FIG4 and Parkinson\u2019s disease. Mov. Disord. Clin. Pract. https:\/\/doi.org\/10.1002\/mdc3.70319 (2025).","DOI":"10.1002\/mdc3.70319"},{"key":"1192_CR24","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1002\/mds.28416","volume":"36","author":"V Skrahina","year":"2021","unstructured":"Skrahina, V. et al. The Rostock International Parkinson\u2019s Disease (ROPAD) study: protocol and initial findings. Mov. Disord. 36, 1005\u20131010 (2021).","journal-title":"Mov. Disord."},{"key":"1192_CR25","doi-asserted-by":"publisher","unstructured":"Smith, L. & Schapira, A. H. V. GBA1 Variants and Parkinson\u2019s disease: mechanisms and treatments. Cells 11, https:\/\/doi.org\/10.3390\/cells11081261 (2022).","DOI":"10.3390\/cells11081261"},{"key":"1192_CR26","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1002\/mds.28195","volume":"35","author":"S Petrucci","year":"2020","unstructured":"Petrucci, S. et al. GBA1-related parkinson\u2019s disease: dissection of genotype-phenotype correlates in a large Italian cohort. Mov. Disord. 35, 2106\u20132111 (2020).","journal-title":"Mov. Disord."},{"key":"1192_CR27","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16499","volume":"32","author":"P G\u00f3mez-Garre","year":"2025","unstructured":"G\u00f3mez-Garre, P. et al. Understanding Parkinson\u2019s disease in Spain: genetic and clinical insights. Eur. J. Neurol. 32, e16499 (2025).","journal-title":"Eur. J. Neurol."},{"key":"1192_CR28","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.ymgme.2011.06.015","volume":"104","author":"M Moraitou","year":"2011","unstructured":"Moraitou, M. et al. \u03b2-Glucocerebrosidase gene mutations in two cohorts of Greek patients with sporadic Parkinson\u2019s disease. Mol. Genet Metab. 104, 149\u2013152 (2011).","journal-title":"Mol. Genet Metab."},{"key":"1192_CR29","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1111\/ene.12315","volume":"21","author":"M Bozi","year":"2014","unstructured":"Bozi, M. et al. Genetic assessment of familial and early-onset Parkinson\u2019s disease in a Greek population. Eur. J. Neurol. 21, 963\u2013968 (2014).","journal-title":"Eur. J. Neurol."},{"key":"1192_CR30","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1111\/j.1468-1331.2012.03817.x","volume":"20","author":"KR Kumar","year":"2013","unstructured":"Kumar, K. R. et al. Glucocerebrosidase mutations in a Serbian Parkinson\u2019s disease population. Eur. J. Neurol. 20, 402\u2013405 (2013).","journal-title":"Eur. J. Neurol."},{"key":"1192_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.694764","volume":"12","author":"E Menozzi","year":"2021","unstructured":"Menozzi, E. & Schapira, A. H. V. Exploring the genotype-phenotype correlation in GBA1-Parkinson disease: clinical aspects, biomarkers, and potential modifiers. Front. Neurol. 12, 694764 (2021).","journal-title":"Front. Neurol."},{"key":"1192_CR32","doi-asserted-by":"publisher","unstructured":"Boura, I. et al. FIG4-related Parkinsonism and the particularities of the I41T mutation: a review of the literature. Genes 15, https:\/\/doi.org\/10.3390\/genes15101344 (2024).","DOI":"10.3390\/genes15101344"},{"key":"1192_CR33","doi-asserted-by":"publisher","unstructured":"Georgiades, M. J. et al. Not so smooth sailing: FIG4-related disease is a differential diagnosis of rapid-onset dystonia-parkinsonism. Mov. Disord. Clin. Pract. https:\/\/doi.org\/10.1002\/mdc3.70049 (2025).","DOI":"10.1002\/mdc3.70049"},{"key":"1192_CR34","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.parkreldis.2019.06.005","volume":"65","author":"TB Ahn","year":"2019","unstructured":"Ahn, T. B. et al. Residual signs of DOPA-responsive dystonia with GCH1 mutation following levodopa treatment are uncommon in Korean patients. Park. Relat. Disord. 65, 248\u2013251 (2019).","journal-title":"Park. Relat. Disord."},{"key":"1192_CR35","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.3346\/jkms.2011.26.9.1244","volume":"26","author":"JH Lee","year":"2011","unstructured":"Lee, J. H. et al. Dopa-responsive dystonia with a novel initiation codon mutation in the GCH1 gene misdiagnosed as cerebral palsy. J. Korean Med. Sci. 26, 1244\u20131246 (2011).","journal-title":"J. Korean Med. Sci."},{"key":"1192_CR36","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1007\/s00702-012-0777-z","volume":"119","author":"T Naiya","year":"2012","unstructured":"Naiya, T. et al. Occurrence of GCH1 gene mutations in a group of Indian dystonia patients. J. Neural Transm. 119, 1343\u20131350 (2012).","journal-title":"J. Neural Transm."},{"key":"1192_CR37","doi-asserted-by":"publisher","first-page":"2480","DOI":"10.1093\/brain\/awu179","volume":"137","author":"NE Mencacci","year":"2014","unstructured":"Mencacci, N. E. et al. Parkinson\u2019s disease in GTP cyclohydrolase 1 mutation carriers. Brain 137, 2480\u20132492 (2014).","journal-title":"Brain"},{"key":"1192_CR38","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1093\/hmg\/ddaa273","volume":"30","author":"SJ Lubbe","year":"2021","unstructured":"Lubbe, S. J. et al. Assessing the relationship between monoallelic PRKN mutations and Parkinson\u2019s risk. Hum. Mol. Genet. 30, 78\u201386 (2021).","journal-title":"Hum. Mol. Genet."},{"key":"1192_CR39","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1093\/brain\/awab456","volume":"145","author":"W Zhu","year":"2022","unstructured":"Zhu, W. et al. Heterozygous PRKN mutations are common but do not increase the risk of Parkinson\u2019s disease. Brain 145, 2077\u20132091 (2022).","journal-title":"Brain"},{"key":"1192_CR40","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1002\/mds.29792","volume":"39","author":"K Sharma","year":"2024","unstructured":"Sharma, K. et al. A Novel p.F385S loss-of-function mutation in an Indian family with Parkinson\u2019s disease. Mov. Disord. 39, 1217\u20131225 (2024).","journal-title":"Mov. Disord."},{"key":"1192_CR41","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s10048-014-0425-x","volume":"16","author":"M Quadri","year":"2015","unstructured":"Quadri, M. et al. An exome study of Parkinson\u2019s disease in Sardinia, a Mediterranean genetic isolate. Neurogenetics 16, 55\u201364 (2015).","journal-title":"Neurogenetics"},{"key":"1192_CR42","doi-asserted-by":"crossref","unstructured":"Salemi, M. et al. A next-generation sequencing study in a cohort of Sicilian patients with Parkinson\u2019s disease. Biomedicines 11 (2023).","DOI":"10.3390\/biomedicines11123118"},{"key":"1192_CR43","doi-asserted-by":"publisher","unstructured":"Georgiou, A. et al. Genetic and environmental factors contributing to Parkinson\u2019s disease: a case-control study in the Cypriot population. Front. Neurol. 10, https:\/\/doi.org\/10.3389\/fneur.2019.01047 (2019).","DOI":"10.3389\/fneur.2019.01047"},{"key":"1192_CR44","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards, S. et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 17, 405\u2013424 (2015).","journal-title":"Genet. Med."},{"key":"1192_CR45","first-page":"782","volume":"43","author":"EDS Rodrigues","year":"2022","unstructured":"Rodrigues, E. D. S. et al. Variant-level matching for diagnosis and discovery: challenges and opportunities. Hum. Mutat. 43, 782\u2013790 (2022).","journal-title":"Hum. Mutat."},{"key":"1192_CR46","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1002\/humu.22768","volume":"36","author":"DG Grimm","year":"2015","unstructured":"Grimm, D. G. et al. The evaluation of tools used to predict the impact of missense variants is hindered by two types of circularity. Hum. Mutat. 36, 513\u2013523 (2015).","journal-title":"Hum. Mutat."},{"key":"1192_CR47","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1002\/humu.21490","volume":"32","author":"S Hicks","year":"2011","unstructured":"Hicks, S., Wheeler, D. A., Plon, S. E. & Kimmel, M. Prediction of missense mutation functionality depends on both the algorithm and sequence alignment employed. Hum. Mutat. 32, 661\u2013668 (2011).","journal-title":"Hum. Mutat."},{"key":"1192_CR48","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-017-1353-5","volume":"18","author":"R Ghosh","year":"2017","unstructured":"Ghosh, R., Oak, N. & Plon, S. E. Evaluation of in silico algorithms for use with ACMG\/AMP clinical variant interpretation guidelines. Genome Biol. 18, 225 (2017).","journal-title":"Genome Biol."},{"key":"1192_CR49","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1136\/jmedgenet-2020-107003","volume":"58","author":"AC Gunning","year":"2021","unstructured":"Gunning, A. C. et al. Assessing performance of pathogenicity predictors using clinically relevant variant datasets. J. Med. Genet. 58, 547\u2013555 (2021).","journal-title":"J. Med. Genet."},{"key":"1192_CR50","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.ajhg.2016.08.016","volume":"99","author":"NM Ioannidis","year":"2016","unstructured":"Ioannidis, N. M. et al. REVEL: an ensemble method for predicting the pathogenicity of rare missense variants. Am. J. Hum. Genet. 99, 877\u2013885 (2016).","journal-title":"Am. J. Hum. Genet."},{"key":"1192_CR51","doi-asserted-by":"publisher","DOI":"10.1126\/science.adg7492","volume":"381","author":"J Cheng","year":"2023","unstructured":"Cheng, J. et al. Accurate proteome-wide missense variant effect prediction with AlphaMissense. Science 381, eadg7492 (2023).","journal-title":"Science"},{"key":"1192_CR52","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1016\/j.ajhg.2024.07.018","volume":"111","author":"M Tejura","year":"2024","unstructured":"Tejura, M. et al. Calibration of variant effect predictors on genome-wide data masks heterogeneous performance across genes. Am. J. Hum. Genet. 111, 2031\u20132043 (2024).","journal-title":"Am. J. Hum. Genet."},{"key":"1192_CR53","doi-asserted-by":"publisher","first-page":"D862","DOI":"10.1093\/nar\/gkv1222","volume":"44","author":"MJ Landrum","year":"2016","unstructured":"Landrum, M. J. et al. ClinVar: public archive of interpretations of clinically relevant variants. Nucleic Acids Res. 44, D862\u2013D868 (2016).","journal-title":"Nucleic Acids Res."},{"key":"1192_CR54","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1002\/mds.30006","volume":"39","author":"SRL Vieira","year":"2024","unstructured":"Vieira, S. R. L. et al. Consensus guidance for genetic counseling in GBA1 variants: a focus on Parkinson\u2019s disease. Mov. Disord. 39, 2144\u20132154 (2024).","journal-title":"Mov. Disord."},{"key":"1192_CR55","doi-asserted-by":"publisher","first-page":"e080952","DOI":"10.1136\/bmj-2024-080952","volume":"388","author":"D Su","year":"2025","unstructured":"Su, D. et al. Projections for prevalence of Parkinson\u2019s disease and its driving factors in 195 countries and territories to 2050: modelling study of Global Burden of Disease Study 2021. BMJ 388, e080952 (2025).","journal-title":"BMJ"},{"key":"1192_CR56","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","volume":"30","author":"RB Postuma","year":"2015","unstructured":"Postuma, R. B. et al. MDS clinical diagnostic criteria for Parkinson\u2019s disease. Mov. Disord. 30, 1591\u20131601 (2015).","journal-title":"Mov. Disord."},{"key":"1192_CR57","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1002\/mds.29902","volume":"39","author":"S Bandres-Ciga","year":"2024","unstructured":"Bandres-Ciga, S. et al. NeuroBooster array: a genome-wide genotyping platform to study neurological disorders across diverse populations. Mov. Disord. 39, 2039\u20132048 (2024).","journal-title":"Mov. Disord."},{"key":"1192_CR58","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1053\/joms.2001.22707","volume":"59","author":"R Todd","year":"2001","unstructured":"Todd, R., Donoff, R. B., Kim, Y. & Wong, D. T. From the chromosome to DNA: restriction fragment length polymorphism analysis and its clinical application. J. Oral. Maxillofac. Surg. 59, 660\u2013667 (2001).","journal-title":"J. Oral. Maxillofac. Surg."},{"key":"1192_CR59","doi-asserted-by":"publisher","first-page":"e288","DOI":"10.1016\/j.jns.2015.08.1005","volume":"357","author":"V Kanellopoulou","year":"2015","unstructured":"Kanellopoulou, V., Panayotopoulou, N., Skoula, I. & Spanaki, C. Phenotype-genotype correlations of GBA1 mutations in Parkinson disease patients from the Island of Crete. J. Neurol. Sci. 357, e288 (2015).","journal-title":"J. Neurol. Sci."},{"key":"1192_CR60","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-024-01421-5","volume":"16","author":"RK Hart","year":"2024","unstructured":"Hart, R. K. et al. HGVS Nomenclature 2024: improvements to community engagement, usability, and computability. Genome Med. 16, 149 (2024).","journal-title":"Genome Med."},{"key":"1192_CR61","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.cell.2018.12.015","volume":"176","author":"K Jaganathan","year":"2019","unstructured":"Jaganathan, K. et al. Predicting splicing from primary sequence with deep learning. Cell 176, 535\u2013548.e524 (2019).","journal-title":"Cell"},{"key":"1192_CR62","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1016\/j.ajhg.2022.10.013","volume":"109","author":"V Pejaver","year":"2022","unstructured":"Pejaver, V. et al. Calibration of computational tools for missense variant pathogenicity classification and ClinGen recommendations for PP3\/BP4 criteria. Am. J. Hum. Genet. 109, 2163\u20132177 (2022).","journal-title":"Am. J. Hum. Genet."},{"key":"1192_CR63","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1002\/humu.24051","volume":"41","author":"J Xiang","year":"2020","unstructured":"Xiang, J., Peng, J., Baxter, S. & Peng, Z. AutoPVS1: an automatic classification tool for PVS1 interpretation of null variants. Hum. Mutat. 41, 1488\u20131498 (2020).","journal-title":"Hum. Mutat."},{"key":"1192_CR64","doi-asserted-by":"publisher","DOI":"10.1002\/cphg.93","volume":"103","author":"SM Harrison","year":"2019","unstructured":"Harrison, S. M., Biesecker, L. G. & Rehm, H. L. Overview of specifications to the ACMG\/AMP variant interpretation guidelines. Curr. Protoc. Hum. Genet. 103, e93 (2019).","journal-title":"Curr. Protoc. Hum. Genet."}],"updated-by":[{"DOI":"10.1038\/s41531-026-01267-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000}}],"container-title":["npj Parkinson's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41531-025-01192-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-025-01192-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-025-01192-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T08:03:00Z","timestamp":1768982580000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41531-025-01192-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,18]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1192"],"URL":"https:\/\/doi.org\/10.1038\/s41531-025-01192-9","relation":{},"ISSN":["2373-8057"],"issn-type":[{"value":"2373-8057","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,18]]},"assertion":[{"value":"29 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41531-026-01267-1","URL":"https:\/\/doi.org\/10.1038\/s41531-026-01267-1","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"I.B. has received research funding from the Project CHAngeing - Connected Hubs in Ageing: Healthy Living to Protect Cerebrovascular Function (grant agreement 101087071), funded by the European Union\u2019s Horizon Europe Program (Excellence Hubs Call\u2014Horizon-WIDERA-2022-ACCESS-04-01, and the European Union-NextGeneration EU (project code: TAEDR-0535850), as well as honoraria for educational and travel grants from AbbVie. P.MI. has received research funding from the Hellenic Precision Medicine Network, the European Union Horizon 2020 research innovation program under the Marie Sklodowska-Curie grant agreement No 101007926 and the European Union\u2019s Horizon Europe Program (Excellence Hubs Call \u2013 Horizon-WIDERA-2022-ACCESS-04-01 under grant agreement No 101087071). G.X. has received honoraria for lecturing, advisory fees, educational grants, and travel grants from ITF Hellas, Innovis, AbbVie, and Teva. S.W.S. receives research support from Cerevel Therapeutics, she is a scientific advisory board member of the Lewy Body Dementia Association, Mission MSA, and the GBA1 Canada Initiative, and an editorial board member of JAMA Neurology and the Journal of Parkinson\u2019s Disease. C.S. has received research funding from the Greek National Precision Medicine Network, the European Union\u2019s Horizon 2020 research innovation program under the Marie Sklodowska-Curie grant agreement No 101007926, the European Union-NextGeneration EU (project code: TAEDR-0535850), and the European Union\u2019s Horizon Europe Program (Excellence Hubs Call \u2013 Horizon-WIDERA-2022-ACCESS-04-01 under grant agreement No 101087071), as well as honoraria for lecturing, advisory fees, educational grants, and travel grants from ITF Hellas, Innovis, Merck Serono, AbbVie, CSL Behring, Roche and Teva. All other authors declare no financial or non-financial competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"354"}}